TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01588184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).
Study: NCT02660957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-determination smoking cessation
Description: a self-help quitting leaflet plus a series of brief interventions using the AWARD model

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: suggest a healthy life style as a placebo comparator
Study: NCT05445362

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diode laser disinfection
Description: - Disinfection with parameter of Power: 1.5 watt, Mode: pulse: SP: Ton=10ms; Toff10ms 50Hz (50% pulse mode), for 5 seconds in spiral movement in apical to coronal direction no stop with non-initiated endodontic tip 200 micron diameter and 15 mm length three times. Irrigation with NaOCl, irradiation with the laser, then irrigation with E.D.T.A and irradiation with the laser, for three times then final rinse with distilled water with paper point dryness in between irrigations.
Study: NCT01588184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).
Study: NCT00092534

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
Description: A 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: A placebo 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study.
Study: NCT02630628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Dosage: start at 2mg twice a day, then taper as per protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Dosage: start at 1g twice a day, then taper as per protocol
Study: NCT01730261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Emotional Regulation Treatment
Description: Emotional Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. EmReg combines didactic and experiential training, and emphasizes skill acquisition and generalization through examination of incidents of emotional dysregulation in one's life and completion of homework assignments. The treatment is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the treatment, to increase their familiarity with the terminology, and to the emotional regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotional regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
Study: NCT05445362

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: revascularization using the standard method Blood Clot
Description: - The root canal Will be over-instrumented using finger plugger size #25 to encourage bleeding up to cemento-enamel junction. The sterile finger plugger size # 25 will be used with sharp strokes into the periapical tissue beyond the apex until bleeding becomes evident at the cervical portion of the canal. Blood column will be left 10 minutes to clot covered by sterile cotton, a collagen orifice plug Collagen plugs will be used as matrix against mineral trioxide aggregate (M.T.A) condensation, M.T.A will be mixed according to the manufacturer's instructions and carried to the cavity with M.T.A carrier (Dovgan M.T.A Carrier) , and then compacted using wet cotton roll on pluggers (S- Kondenser) . Finally the cavity will be restored with a glass ionomer base and light cure composite resin .
Study: NCT00754234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Pyramid menu days 1, 2, 3, 4, 5, 6 or 7
Description: Iron absorption measured from one of seven different menus fed for 1 day each, in randomized order for each subject, with feedings separated by 2 weeks
Study: NCT04004663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: PF-06651600 100 milligrams (mg) will be provided in 4 different oral formulations (Treatment A,B,C,D). Participants will receive each formulation in one of 4 periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: PF-06651600 100 milligrams (mg) will be provided in 4 different oral formulations (Treatment A,B,C,D). Participants will receive each formulation in one of 4 periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: PF-06651600 100 milligrams (mg) will be provided in 4 different oral formulations (Treatment A,B,C,D). Participants will receive each formulation in one of 4 periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: PF-06651600 100 milligrams (mg) will be provided in 4 different oral formulations (Treatment A,B,C,D). Participants will receive each formulation in one of 4 periods
Study: NCT00310024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01697592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
Study: NCT01602861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: One tablet per day (25 mg Spironolactone/placebo) for the first three months. Subsequently dosage is increased to two tablets per day (50 mg Spironolactone/placebo) for the rest of the study.~In case of hyperkaliemia (\>5,5 mmol/L) or intolerable side effects dosage will be reduced to one tablet per day (25 mg Spironolactone/placebo).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04527718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo as a single SC injection on Day 1;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo as a single SC injection on Day 1;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo as a single SC injection on Day 1;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo as a single SC injection on Day 1;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo as a single SC injection on Day 1;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611
Description: 611 as a single SC injection on Day 1;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611
Description: 611 as a single SC injection on Day 1;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611
Description: 611 as a single SC injection on Day 1;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611
Description: 611 as a single SC injection on Day 1;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611
Description: 611 as a single SC injection on Day 1;
Study: NCT00664573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baminercept alfa (BG9924)
Description: dosage administered as per Biogen-Idec protocol

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baminercept alfa (BG9924)
Description: dosage administered as per Biogen-Idec protocol

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baminercept alfa (BG9924)
Description: dosage administered as per Biogen-Idec protocol

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baminercept alfa (BG9924)
Description: dosage administered as per Biogen-Idec protocol
Study: NCT03066713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Off French Fry
Description: Skin Off French Fries will be provided at breakfast and lunch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin On French Fry
Description: Skin On French Fries will be provided at breakfast and lunch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hash brown
Description: Hash brown potatoes will be provided at breakfast and lunch.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate control
Description: A pancake will be provided at breakfast, and pretzels will be provided at lunch.
Study: NCT00959114

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALV003
Description: ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ALV003 placebo
Description: ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).
Study: NCT04068844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise training, either whole body or isolated single leg

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise training, either whole body or isolated single leg

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise training, either whole body or isolated single leg

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise training, either whole body or isolated single leg
Study: NCT04094038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olimel N12
Description: A mixture of glucose, lipids, amino acids.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose IV
Description: Glucose 5%
Study: NCT01275625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIV therapy
Description: Combivir one tablet BD with maraviroc 300mg BD for 48 weeks
Study: NCT02311712

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capsule sponge
Description: Capsule sponge cytology examination coupled with H\&E staining analysed for the presence of atypia and p53 immunohistochemistry
Study: NCT02025725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide Nasal Spray
Description: nasal spray formulation of metoclopramide
Study: NCT00594269

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risperidone
Description: Discontinuation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Discontinuation
Study: NCT00594269

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Citalopram
Description: Discontinuation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sertraline
Description: Discontinuation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paroxetine
Description: Discontinuation
Study: NCT03750552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ampreloxetine
Description: Oral tablet, QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet, QD
Study: NCT02776358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fidelity Simulation
Description: A HFS session for an asthma attack require:~* a 5 minutes briefing session: case and equipments presentation and choice of participants~* 15 minutes of actual simulation~* 40 minutes of debriefing~A pre and a post test will be taken by the students before and after the session and a satisfaction questionnaire at the end of the course.~Also, another test will be done after 7 days of the course.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video case
Description: a video case (or video box) session in which students will attend a video-projection of a real case of an asthma attack and discuss with the trainer the different steps of the assessement and management of an asthma attack.~A pre and a post test will be taken by the students before and after the session and a satisfaction questionnaire at the end of the course.~Also, another test will be done after 7 days of the course.
Study: NCT05833750

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reflexology
Description: In the intervention group, reflexology was applied to the feet twice a week for 8 weeks.
Study: NCT01766557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-controlled nutritional intervention with fish protein diet
Description: After a controlled NCEP-based diet for 3 months, women are assigned to a cod fillet diet. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. Then, each group receive the other diet for an additional 3 months period. The fish protein intake come from cod fillets and correspond to 50% of total protein, the remaining dietary proteins being from BPVEM (20%) and vegetable (30%). Lunches incorporating cod fillets are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. Alcohol is strictly prohibited during all periods.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semi-controlled intervention with other animal proteins
Description: Prior to experimental period, participants follow a controlled NCEP-based diet for 3 months. Then women are assigned to a diet containing beef, pork, veal, eggs, milk and milk products. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. The two diets are isoenergetic. The protein intake from BPVEM correspond to 70% of total protein, other dietary proteins are from vegetable (30%) origin. Lunches incorporating animal proteins are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. The content in n-3 fatty acids is adjusted to provide equivalent amounts of n-3 fatty acids then in the cod protein diet. Alcohol is strictly prohibited during all periods.
Study: NCT01495429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central venous catheter
Description: Placement of a peripherally inserted central venous catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central venous catheter
Description: Placement of a centrally inserted central venous catheter
Study: NCT02025725

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: nasal spray formulation with vehicle only
Study: NCT04011553

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality based Rehabilitation Program
Description: Virtual reality-based rehabilitation was implemented via MarVAJED system. At first the sensors of MarVAJED® were placed under and above the knee joint and then it was calibrated. The content of the game programs included in the MarVAJED system and how to perform these games with the exercises were explained to the participants. We used games called Crazy Wings and Blasting Ball included in the MarVAJED®.There was a bird figure in Crazy Wings game and represented knee joint of participants. Although the bird figure moved upwards during knee flexion, it moved downward in knee extension, there were some obstacles on the way of the bird went. The subjects were asked to follow the bird figure visually and to pass through the obstacles by flexing or extending their knees when they encountered obstacles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality based Rehabilitation Program
Description: Virtual reality-based rehabilitation was implemented via MarVAJED system. At first the sensors of MarVAJED® were placed under and above the knee joint and then it was calibrated. The content of the game programs included in the MarVAJED system and how to perform these games with the exercises were explained to the participants. We used games called Crazy Wings and Blasting Ball included in the MarVAJED®.There was a bird figure in Crazy Wings game and represented knee joint of participants. Although the bird figure moved upwards during knee flexion, it moved downward in knee extension, there were some obstacles on the way of the bird went. The subjects were asked to follow the bird figure visually and to pass through the obstacles by flexing or extending their knees when they encountered obstacles.
Study: NCT04483050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hip protection orthosis
Description: Experimental group would wear hip protection orthosis over 12 hours a day for 1 year.
Study: NCT03412669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supporting Addiction Affected Families Effectively
Description: Counselling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Information sheet
Study: NCT04508894

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Supraclavicular Brachial Plexus Block with bupivacaine
Description: drug: 20 ml 0.5%bupivacaine plus 20 ml 0.9% normal saline is administered around the brachial plexus on the operative side Drug: IM diclofenac sodium (75 mg amp) is injected if VAS more than 4.~Device: ultrasound-guided supraclavicular Brachial Plexus nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supraclavicular Brachial Plexus Block with Ketamine
Description: drug: 20 ml 0.5%bupivacaine, 20 ml 0.9% normal saline plus 1mg\\kg ketamine is administered around the brachial plexus on the operative side Drug: IM diclofenac sodium (75 mg amp) is injected if VAS more than 4.~Device: ultrasound-guided supraclavicular Brachial Plexus nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supraclavicular Brachial Plexus Block with Dexmedetomidine
Description: drug: 20 ml 0.5%bupivacaine, 20 ml 0.9% normal saline plus 1µg\\kg dexmedetomidine is administered around the brachial plexus on the operative side Drug: IM diclofenac sodium (75 mg amp) is injected if VAS more than 4.~Device: ultrasound-guided supraclavicular Brachial Plexus nerve block
Study: NCT04649398

Intervention type: DRUG
Intervention: Nimodipine
Description: If application of nimodipine is clinically indicated patients will be enrolled in the study protocol according to the inclusion and exclusion criteria. The clinically appropriate route of administration will be administered according to the recommended regimen of the study drug; i.e. within the first 10-14 days intra-venous infusion and thereafter oral administration. Intra-arterial infusion will be performed due to severe cerebral vasospasm with impending stroke.

Intervention type: DRUG
Intervention: Nimodipine
Description: If application of nimodipine is clinically indicated patients will be enrolled in the study protocol according to the inclusion and exclusion criteria. The clinically appropriate route of administration will be administered according to the recommended regimen of the study drug; i.e. within the first 10-14 days intra-venous infusion and thereafter oral administration. Intra-arterial infusion will be performed due to severe cerebral vasospasm with impending stroke.

Intervention type: DRUG
Intervention: Nimodipine
Description: If application of nimodipine is clinically indicated patients will be enrolled in the study protocol according to the inclusion and exclusion criteria. The clinically appropriate route of administration will be administered according to the recommended regimen of the study drug; i.e. within the first 10-14 days intra-venous infusion and thereafter oral administration. Intra-arterial infusion will be performed due to severe cerebral vasospasm with impending stroke.
Study: NCT02105116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor lymphocytes
Description: Undergo infusion of donor lymphocytes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Given IV